Trial
NCT02265510
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
Solid Tumors
Intervention
INCB052793
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-17